Your search returned 2 results.

Results
	1.	Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. [electronic resource] by Lindström, Linda Sofie Karlsson, Eva Wilking, Ulla M Johansson, Ulla Hartman, Johan Lidbrink, Elisabet Kerstin Hatschek, Thomas Skoog, Lambert Bergh, Jonas Producer: 20120924 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 30 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. [electronic resource] by Bergh, Jonas Jönsson, Per-Ebbe Lidbrink, Elisabet Kerstin Trudeau, Maureen Eiermann, Wolfgang Brattström, Daniel Lindemann, Justin P O Wiklund, Fredrik Henriksson, Roger Producer: 20120730 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 30 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search